Colorectal cancer is increasingly appearing in people who are too young to have been considered part of the disease’s traditional risk group. A new roadmap published in Nature Reviews Cancer argues that preventing this rise will require more than simply lowering the age of screening. Researchers say early-onset colorectal cancer, defined as disease diagnosed before age 50, is a complex and rapidly evolving public-health challenge whose causes remain only partly understood. Rates are increasing in many regions, while younger patients can face delayed diagnosis because symptoms such as rectal bleeding, abdominal pain, altered bowel habits or unexplained weight loss are often attributed to less serious conditions. The review brings together evidence on lifestyle, metabolism, early-life exposures, gut microbes, genetics and social behaviour, and proposes a coordinated strategy for discovering which factors actually cause cancer at younger ages. Its central message is urgent: science must move from observing associations to identifying mechanisms that can be translated into practical prevention.
The most familiar suspects are already linked to colorectal cancer in adults of all ages. Obesity, insulin resistance, type 2 diabetes, metabolic dysfunction, diets low in fibre and high in ultra-processed foods, excess intake of red or processed meat, alcohol consumption and physical inactivity have all been associated with increased risk. These factors can influence the intestine through several biological routes. Excess adipose tissue can promote chronic, low-grade inflammation and alter levels of hormones and growth factors, including insulin and insulin-like growth factor signalling. Metabolic disease may affect immune surveillance, tissue repair and cellular proliferation. Diet can change the amount of fibre-derived short-chain fatty acids reaching the colon, alter bile-acid metabolism and influence the physical and chemical environment in which intestinal cells live. Yet the review cautions that these relationships do not automatically prove causation. A risk factor may be a marker for another exposure, its effects may vary across life stages, or several modest influences may combine to push susceptible tissue toward malignancy.
That question of timing is one of the most important scientific gaps. Colorectal cancer generally develops through a multistep process in which cells acquire genetic and epigenetic alterations, evade normal growth controls and interact with the surrounding tissue. In early-onset disease, researchers are asking whether risk begins accumulating in childhood, adolescence or even before birth. Early-life nutrition, antibiotic exposure, infections, inflammation, psychosocial stress and patterns of weight gain could potentially influence how the immune system, metabolism and intestinal barrier mature. These exposures may not cause a visible tumour immediately. Instead, they could establish biological conditions that make later mutations more consequential or change which cell populations are able to expand. The researchers emphasize that the relevant window may differ from one person to another and that risk may be shaped by trajectories rather than single events. Understanding those trajectories will require studies that follow people over decades, rather than relying exclusively on questionnaires completed after cancer has been diagnosed.
The gut microbiome has emerged as another possible piece of the puzzle, although it remains far from a clinically proven explanation. Trillions of bacteria and other microorganisms inhabit the digestive tract, where they interact with food, host cells and the immune system. Microbial communities can produce metabolites that support the intestinal lining, but they can also generate compounds capable of promoting inflammation, damaging DNA or altering cell signalling. Antibiotics, diet, obesity, geography and other environmental conditions can change the composition and activity of these communities. The key issue is not simply which bacterial species are present, but what they are doing, where they are located and how their functions change over time. A microbial signature found in a patient with colorectal cancer might be a consequence of the tumour, treatment or dietary changes rather than an initiating cause. The roadmap therefore calls for mechanistic studies that connect microbial genes and metabolites to specific processes in tumour development, alongside carefully designed human studies that can separate cause from consequence.
Genetics remains essential, but the authors describe early-onset colorectal cancer as a disease that cannot be explained by inherited mutations alone. A proportion of younger patients carry pathogenic variants in genes associated with hereditary cancer syndromes, including those involved in DNA mismatch repair, polyposis and other systems that protect cells from genomic damage. Genetic counselling and testing can therefore identify high-risk individuals and enable earlier surveillance for patients and relatives. However, most cases do not arise from a single inherited alteration with a straightforward clinical pathway. Common genetic variants may each contribute a small amount of risk, while environmental exposures and biological changes could determine whether that predisposition becomes cancer. Researchers must also examine how tumour cells from younger patients differ molecularly from those in older adults, and whether apparent differences reflect distinct causes, different tissue environments or changes in diagnosis and healthcare access. Integrating inherited genetics, tumour sequencing, immune profiles, microbiome data and exposure histories could reveal biologically meaningful subgroups rather than treating all early-onset cases as one condition.
Prevention is especially difficult because younger adults are not a uniform population and may not interact regularly with the healthcare system. Many are below the age at which average-risk screening has traditionally begun, while others face barriers related to cost, insurance, geography, work schedules, childcare, stigma or distrust. A strategy designed around colonoscopy alone is unlikely to reach everyone who could benefit. Non-invasive tests based on stool, blood or other biological signals may eventually help identify people who need diagnostic evaluation, but such tools must be rigorously validated in younger populations. A test that performs well in older adults may not have the same predictive value when disease prevalence is lower or when tumours have different molecular features. Prevention could also include interventions aimed at weight, diet, physical activity, metabolic health and smoking or alcohol use, but public-health messaging must avoid blaming individuals for a disease shaped by social and environmental conditions. Effective programmes will need to be affordable, culturally appropriate, accessible and evaluated for unintended consequences.
The roadmap proposes a transdisciplinary framework intended to connect discoveries across levels of research. Population scientists can identify patterns in incidence and exposure; epidemiologists can test associations in large cohorts; molecular biologists can investigate cellular pathways; microbiologists can examine host–microbe interactions; behavioural scientists can study how people respond to prevention programmes; and implementation researchers can determine whether interventions work in real healthcare settings. These fields often operate with different measurements, timelines and definitions of success. A coordinated approach would require common data standards, representative study populations, repeated biological sampling and methods capable of analysing interacting exposures. Statistical models may help estimate cumulative risk, but they must be paired with laboratory experiments and natural experiments that strengthen causal inference. The researchers highlight emerging global efforts such as the Cancer Grand Challenges team PROSPECT as examples of the scale of collaboration needed. International partnerships are particularly important because early-onset colorectal cancer trends may reflect region-specific diets, healthcare systems, environmental exposures and demographic changes.
Patient and public involvement is presented as a scientific necessity rather than a ceremonial addition. People who have experienced early-onset colorectal cancer can identify symptoms, diagnostic delays and treatment burdens that may be invisible in clinical datasets. Their perspectives can help researchers choose outcomes that matter, design studies that participants are willing to join and communicate risk without creating unnecessary fear. Public engagement may also improve recruitment from communities that have historically been underrepresented in research, making findings more applicable beyond affluent or highly connected populations. Policymakers, meanwhile, will need evidence about cost, feasibility and equity before introducing new screening recommendations or prevention programmes. The review argues that urgency should not lead to premature claims about unproven supplements, microbiome treatments or highly restrictive diets. Strong evidence must distinguish plausible mechanisms from interventions that actually reduce cancer incidence or mortality. The goal is not merely to detect tumours earlier, but to prevent the biological and social conditions that allow them to develop.
The researchers ultimately frame the rise of early-onset colorectal cancer as a warning that the causes of cancer are changing faster than many prevention systems. Reversing the trend will require attention to the entire life course, from early development and metabolic health to microbial ecology, inherited susceptibility and access to care. It will also demand studies that include diverse populations and follow participants long enough to capture exposures before diagnosis. No single factor is likely to explain the global increase, and no single intervention is likely to stop it. But combining causal risk-factor discovery with patient-informed design and practical implementation could turn a troubling epidemiological signal into an opportunity for prevention. The roadmap’s broader challenge is directed at scientists, health systems and governments alike: treat younger adults as a priority population, invest in collaborative research before the disease appears, and convert evidence into interventions capable of protecting future generations from colorectal cancer.
Subject of Research: Prevention and causal risk-factor discovery for early-onset colorectal cancer in people under age 50
Article Title: Shaping the future of early-onset colorectal cancer prevention
Article References: Tian, R., Azadnajafabad, S., Waters, E.A. et al. “Shaping the future of early-onset colorectal cancer prevention.” Nature Reviews Cancer (2026). https://doi.org/10.1038/s41568-026-00965-5
Image Credits: AI Generated
DOI: 10.1038/s41568-026-00965-5
Keywords: early-onset colorectal cancer, cancer prevention, gut microbiome, lifestyle risk factors, early-life exposures, metabolic health, cancer screening, transdisciplinary research
Tags: adolescent colorectal cancer risk factorscomprehensive prevention strategies for early colorectalearly diagnosis challenges in young colorectal cancer patientsEarly-onset colorectal cancer preventiongenetic and environmental causes of early-onset colorectal cancergut microbiome and colorectal cancerimpact of diet and processed foods on colon cancerlifestyle influences on early colorectal cancermechanisms of colorectal carcinogenesis in young adultsobesity and metabolic health in colorectal cancer riskpublic health strategies for young colorectal cancer patientsregional variations in early-onset colorectal cancer incidence
